This refresh
Data-driven refresh July 6, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,230 tickers); 1,788 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90
Health Information Services · price $22.86 · 1Y $24.37 · 5Y $35.68 · 10Y $52.93
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 23.3x B+ · PEG 0.59 A-
Why now. Doximity is a high-quality compounder leveraging its essential digital platform for medical professionals, evidenced by a robust 30.4% profit margin and impressive $326m in free cash flow. With a compelling 0.59 PEG ratio, the market is underpricing its consistent 13.1% revenue growth, driven by increasing engagement with workflow tools like its HIPAA-compliant AI assistant, Ask, and sponsored content. The core thesis rests on Doximity's ability to continue monetizing its deeply embedded position within the daily routines of U.S. medical professionals.
Moat. Doximity's durable edge stems from powerful network effects within its Doximity platform, where a personalized newsfeed and professional updates from peers create high switching costs and a self-reinforcing loop for medical professionals. This deep integration into clinical workflows, coupled with HIPAA-compliant tools like Ask and Scribe, fosters a sticky user base that is difficult for competitors to dislodge. The company's 20.6% ROE is a direct result of this category leadership and pricing power derived from being the go-to digital hub for U.S. doctors.
Risk. The primary bear case against Doximity centers on potential deceleration in its core advertising revenue, particularly from pharmaceutical manufacturers, as competition for physician attention intensifies or marketing budgets shift. Despite strong margins, the company's current price of $22.86 is still significantly below its 52-week high of $76.51, indicating substantial volatility with a beta of 1.29, and its 6.5x P/S ratio remains elevated for a name growing at 13.1%. A sustained decline in active user engagement or a significant slowdown in new client acquisition would confirm the bear thesis.
Horizon. 1-3 yr $24.37 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.68 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $52.93 if current growth sustains into durable earnings power.
2. INTU — Intuit Inc. · score 89.3
Software - Application · price $272.14 · 1Y $486.61 · 5Y $614.33 · 10Y $787.87
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.6x A- · PEG 0.71 A-
Why now. Software - Application · market cap $74.4b. Down 67% from 52-week high of $813.70 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.71 — paying under fair value for the growth rate. 32 sell-side analysts rate this a Buy with a mean 1-yr target of $486.61 (implying +79% upside).
Moat. Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 169% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 67% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $486.61 (analyst consensus (n=32)) — multiple re-rating thesis requires a catalyst. 5 yr $614.33 at ~18% CAGR — dividend + buyback compounding. 10 yr $787.87 if the moat survives secular pressure.
3. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $90.28 · 1Y $103.82 · 5Y $152.01 · 10Y $225.49
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 14.1x A- · PEG 0.51 A-
Why now. The integrated online curriculum and learning‑management platform for virtual and blended public schools is scaling at a rapid clip, delivering 17.9% YoY revenue growth, $414 m of free cash flow and a PEG of 0.51 that signals deep‑value growth – the compounding engine is the relentless shift of districts toward digital‑first instruction, and it will keep accelerating as funding for hybrid education expands.
Moat. Stride’s end‑to‑end suite—curriculum, software, enrollment and progress‑tracking tools—locks districts into a single data‑rich ecosystem, creating high switching costs and a defensible moat. That stickiness fuels a ROE of 18.8%, derived from pricing power in a niche where schools pay a premium for a turnkey virtual‑learning solution that competitors cannot replicate quickly.
Risk. The bull rally hinges on continued double‑digit growth; a slowdown to sub‑10% would erode the valuation, especially after a 52‑week high of $171.17 versus today’s $90.28, a >45% price collapse that could deepen. Bears point to the modest profit margin of 12.2% and the lack of analyst coverage (only 2) as warning signs—if margin contracts or growth stalls, the stock could retest the low‑52‑week range.
Horizon. 1-3 yr $103.82 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $152.01 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $225.49 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89
Software - Application · price $218.07 · 1Y $280.66 · 5Y $410.91 · 10Y $609.56
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 12.5x A · PEG 0.60 A-
Why now. Adobe’s Digital Experience platform is now the core engine for enterprise marketers, fueling a 10.5% YoY revenue growth while the stock trades at a rock‑low PEG of 0.6 and delivers a staggering 62.8% ROE, proving capital efficiency. The subscription‑based Creative Cloud and Experience Cloud lock in recurring cash, expanding free cash flow at double‑digit rates. The thesis collapses if the sticky subscription base stalls, because all compounding hinges on continued adoption of the integrated platform.
Moat. The Creative Cloud suite creates high switching costs: enterprises embed Photoshop, Premiere and Illustrator into daily workflows, making migration costly and time‑consuming. Adobe’s integrated Digital Experience stack deepens that lock‑in by offering end‑to‑end analytics, commerce and personalization, a combination rivals cannot replicate quickly. This pricing power drives the 62.8% ROE, as Adobe can command premium subscription fees while maintaining a 28.7% profit margin.
Risk. A slowdown in enterprise marketing spend could blunt Digital Experience growth, and the 10.5% revenue growth rate is already modest for a high‑growth name; a dip to sub‑5% would compress margins that sit at 28.7%. The stock’s beta of 1.43 amplifies any market pull‑back, and a debt‑to‑equity of 0.61 limits financial flexibility if cash flow falters. A clear bear signal would be a quarterly revenue growth miss coupled with margin contraction below 25%, eroding the subscription‑driven cash flow narrative.
Horizon. 1-3 yr $280.66 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $410.91 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $609.56 if current growth sustains into durable earnings power.
5. PCTY — Paylocity Holding Corporation · score 88.3
Software - Application · price $113.77 · 1Y $152.58 · 5Y $192.63 · 10Y $247.04
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 24.3x B+ · PEG 0.91 B+
Why now. Software - Application · market cap $6.1b. Down 42% from 52-week high of $197.78 — deep drawdown territory. Revenue growing +15%, comfortably above the S&P median. PEG 0.91 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $152.58 (implying +34% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 189% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. AI-native re-pricing — GPT-class models are compressing the cost of features that took years to build; the moat thesis depends on owning the workflow, not just the feature set.
Horizon. 1-3 yr $152.58 (analyst consensus (n=19)) — multiple re-rating thesis requires a catalyst. 5 yr $192.63 at ~11% CAGR — dividend + buyback compounding. 10 yr $247.04 if the moat survives secular pressure.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.4
Drug Manufacturers - Specialty & Generic · price $174.10 · 1Y $195.99 · 5Y $247.43 · 10Y $317.32
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 26.8x B · PEG 0.49 A
Why now. Drug Manufacturers - Specialty & Generic · market cap $17.5b. Trading near 52-week high of $175.02 — momentum setup, limited technical margin of safety. Revenue growing +21%, comfortably above the S&P median. PEG 0.49 — paying under fair value for the growth rate. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $195.99 (implying +13% upside).
Moat. Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $195.99 (analyst consensus (n=28)) — multiple re-rating thesis requires a catalyst. 5 yr $247.43 at ~7% CAGR — dividend + buyback compounding. 10 yr $317.32 if the moat survives secular pressure.
7. ADMA — ADMA Biologics, Inc. · score 87.1
Biotechnology · price $9.16 · 1Y $17.60 · 5Y $22.22 · 10Y $28.50
FCF $108m C · Rev +19.6% B+ · D/E 1.11 C · P/E 13.5x A- · PEG 0.69 A-
Why now. Biotechnology · market cap $2.1b. Down 55% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.69 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $17.60 (implying +92% upside).
Moat. Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk. Down 55% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — multiple re-rating thesis requires a catalyst. 5 yr $22.22 at ~19% CAGR — dividend + buyback compounding. 10 yr $28.50 if the moat survives secular pressure.
8. NVDA — NVIDIA Corporation · score 86.3
Semiconductors · price $195.55 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 29.9x B · PEG 0.60 A-
Why now. The bull case hinges on NVIDIA’s Compute & Networking data‑center AI platform, which is driving revenue at a staggering 65.5% YoY, while the business is generating massive $119.1b of free cash flow and trades at a razor‑thin 0.6 PEG, meaning growth is cheap relative to earnings. This compounding engine will keep cash conversion high and fund continued AI‑chip leadership, and the thesis rests on the relentless expansion of AI workloads in the data‑center market.
Moat. NVIDIA’s moat comes from its end‑to‑end GPU‑plus‑software stack that locks in data‑center customers with high switching costs and unmatched performance, delivering an industry‑leading 81.7% ROE powered by pricing power in AI accelerators. The ultra‑low 0.07 debt‑to‑equity ratio and 63% profit margin give it financial flexibility to reinvest in R&D, keeping competitors far behind in architecture and ecosystem integration.
Risk. The bear case centers on the volatility of AI spending; a slowdown would expose NVIDIA’s lofty PE 29.9 and high beta 2.21, making the stock vulnerable to a sharp re‑rating. If data‑center demand contracts, margins could erode and the stock could fall back toward its 52‑week low of $157.34, confirming the downside thesis.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.7
Information Technology Services · price $27.13 · 1Y $41.75 · 5Y $52.71 · 10Y $67.60
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 17.3x A- · PEG 0.87 B+
Why now. Information Technology Services · market cap $4.1b. Down 42% from 52-week high of $47.11 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.87 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $41.75 (implying +54% upside).
Moat. ROE 32% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 118% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — multiple re-rating thesis requires a catalyst. 5 yr $52.71 at ~14% CAGR — dividend + buyback compounding. 10 yr $67.60 if the moat survives secular pressure.
10. HRMY — Harmony Biosciences Holdings, Inc. · score 85.2
Biotechnology · price $37.01 · 1Y $44.91 · 5Y $56.70 · 10Y $72.71
FCF $342m C · Rev +21.5% A- · D/E 0.18 B+ · P/E 14.9x A- · PEG 0.69 A-
Why now. Biotechnology · market cap $2.1b. 9% off the 52-week high of $40.87. Revenue growing +22%, comfortably above the S&P median. PEG 0.69 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $44.91 (implying +21% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — multiple re-rating thesis requires a catalyst. 5 yr $56.70 at ~9% CAGR — dividend + buyback compounding. 10 yr $72.71 if the moat survives secular pressure.
11. IT — Gartner, Inc. · score 84.3
Information Technology Services · price $135.11 · 1Y $165.00 · 5Y $208.31 · 10Y $267.15
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 13.4x A · PEG 0.55 A-
Why now. Information Technology Services · market cap $9.0b. Down 67% from 52-week high of $403.96 — deep drawdown territory. PEG 0.55 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $165.00 (implying +22% upside).
Moat. FCF converts 170% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 67% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — multiple re-rating thesis requires a catalyst. 5 yr $208.31 at ~9% CAGR — dividend + buyback compounding. 10 yr $267.15 if the moat survives secular pressure.
12. EPAM — EPAM Systems, Inc. · score 83.8
Information Technology Services · price $86.85 · 1Y $142.82 · 5Y $180.31 · 10Y $231.24
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 12.5x A · PEG 0.45 A
Why now. Information Technology Services · market cap $4.5b. Down 61% from 52-week high of $222.53 — deep drawdown territory. Revenue growing +15%, comfortably above the S&P median. PEG 0.45 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $142.82 (implying +64% upside).
Moat. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 61% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.43 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $142.82 (analyst consensus (n=17)) — multiple re-rating thesis requires a catalyst. 5 yr $180.31 at ~16% CAGR — dividend + buyback compounding. 10 yr $231.24 if the moat survives secular pressure.
13. DXCM — DexCom, Inc. · score 83.3
Medical Devices · price $72.38 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.47 B · P/E 31.1x B · PEG 1.33 B
Why now. Medical Devices · market cap $27.9b. 20% off the 52-week high of $89.98. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $85.24 (implying +18% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 31% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 154% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Beta 1.45 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
14. CARG — CarGurus, Inc. · score 82.5
Auto & Truck Dealerships · price $35.66 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 18.8x B+ · PEG 1.10 B+
Why now. Auto & Truck Dealerships · market cap $3.2b. 10% off the 52-week high of $39.42. Revenue growing +14%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $37.38 (implying +5% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 63% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
15. META — Meta Platforms, Inc. · score 82.2
Internet Content & Information · price $600.29 · 1Y $828.17 · 5Y $1,046 · 10Y $1,341
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 21.8x B · PEG 0.84 B+
Why now. Internet Content & Information · market cap $1.5T. Down 25% from 52-week high of $796.25 — deep drawdown territory. Revenue growing +22%, comfortably above the S&P median. PEG 0.84 — paying under fair value for the growth rate. 58 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $828.17 (implying +38% upside).
Moat. Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.5T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $828.17 (analyst consensus (n=58)) — multiple re-rating thesis requires a catalyst. 5 yr $1,046 at ~12% CAGR — dividend + buyback compounding. 10 yr $1,341 if the moat survives secular pressure.
16. VEEV — Veeva Systems Inc. · score 82.1
Health Information Services · price $192.01 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 34.0x C+ · PEG 0.87 B+
Why now. Health Information Services · market cap $31.2b. Down 38% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.87 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $244.59 (implying +27% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 38% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 34x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
17. RMD — ResMed Inc. · score 81.9
Medical Instruments & Supplies · price $218.40 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
FCF $1.8b C+ · Rev +9.8% B · D/E 0.13 B+ · P/E 21.0x B+ · PEG 1.23 B
Why now. Medical Instruments & Supplies · market cap $31.7b. Down 26% from 52-week high of $293.81 — deep drawdown territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $260.60 (implying +19% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
18. CVSA — Covista Inc. · score 81.6
Education & Training Services · price $129.56 · 1Y $156.25 · 5Y $197.26 · 10Y $252.98
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 18.9x B · PEG 0.88 B+
Why now. Education & Training Services · market cap $4.4b. 17% off the 52-week high of $156.26. Revenue growing +13%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $156.25 (implying +21% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 144% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — multiple re-rating thesis requires a catalyst. 5 yr $197.26 at ~9% CAGR — dividend + buyback compounding. 10 yr $252.98 if the moat survives secular pressure.
19. QCOM — QUALCOMM Incorporated · score 80
Semiconductors · price $186.48 · 1Y $215.42 · 5Y $271.96 · 10Y $348.78
FCF $12.5b A- · Rev +13.7% B+ · D/E 0.56 C+ · P/E 20.0x B+ · PEG 0.56 A-
Why now. Semiconductors · market cap $196.5b. Down 28% from 52-week high of $259.92 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.56 — paying under fair value for the growth rate. 31 sell-side analysts rate this a Hold with a mean 1-yr target of $215.42 (implying +16% upside).
Moat. Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 126% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Beta 1.64 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
Horizon. 1-3 yr $215.42 (analyst consensus (n=31)) — multiple re-rating thesis requires a catalyst. 5 yr $271.96 at ~8% CAGR — dividend + buyback compounding. 10 yr $348.78 if the moat survives secular pressure.
20. MELI — MercadoLibre, Inc. · score 79.9
Internet Retail · price $1805.68 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +34.3% A · D/E 1.70 C+ · P/E 47.6x C · PEG 1.09 B+
Why now. Internet Retail · market cap $91.5b. Down 29% from 52-week high of $2548.50 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,209 (implying +22% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $91.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Trailing P/E 48x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
21. PODD — Insulet Corporation · score 79.4
Medical Devices · price $159.77 · 1Y $240.25 · 5Y $351.75 · 10Y $521.80
FCF $416m C · Rev +30.7% A · D/E 0.78 C+ · P/E 37.3x C+ · PEG 1.45 B
Why now. Medical Devices · market cap $11.1b. Down 55% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 24 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $240.25 (implying +50% upside).
Moat. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 55% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $240.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $351.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $521.80 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 78.7
Footwear & Accessories · price $105.67 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.1x B+ · PEG 1.30 B
Why now. Footwear & Accessories · market cap $14.7b. 16% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +20% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 77.4
Entertainment · price $76.02 · 1Y $113.94 · 5Y $166.82 · 10Y $247.47
FCF $11.9b A- · Rev +15.9% B+ · D/E 0.54 B · P/E 24.5x B · PEG 1.53 C+
Why now. Entertainment · market cap $320.1b. Down 41% from 52-week high of $129.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $113.94 (implying +50% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $320.1b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.52 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $113.94 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $166.82 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $247.47 if current growth sustains into durable earnings power.
24. FISV — Fiserv, Inc. · score 75.8
Sector n/a · price $51.78 · 1Y $70.00 · 5Y $88.37 · 10Y $113.34
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.8x A- · PEG 2.44 C
Why now. Sector n/a · market cap $27.6b. Down 71% from 52-week high of $175.92 — deep drawdown territory. 26 sell-side analysts rate this a Hold with a mean 1-yr target of $70.00 (implying +35% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 71% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $88.37 at ~11% CAGR — dividend + buyback compounding. 10 yr $113.34 if the moat survives secular pressure.
25. YUMC — Yum China Holdings, Inc. · score 75.3
Restaurants · price $42.49 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +4.4% C+ · D/E 0.38 A- · P/E 16.3x B+ · PEG 1.04 B+
Why now. Restaurants · market cap $14.7b. Down 27% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +44% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
26. ULTA — Ulta Beauty, Inc. · score 74.9
Specialty Retail · price $452.49 · 1Y $627.25 · 5Y $918.36 · 10Y $1,362
FCF $1.1b C+ · Rev +9.7% B · D/E 0.89 B · P/E 17.0x B+ · PEG 1.60 C+
Why now. Specialty Retail · market cap $19.5b. Down 37% from 52-week high of $714.97 — deep drawdown territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $627.25 (implying +39% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $627.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $918.36 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,362 if current growth sustains into durable earnings power.
27. EME — EMCOR Group, Inc. · score 73.9
Engineering & Construction · price $787.29 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +16.6% B+ · D/E 0.13 A- · P/E 26.5x B · PEG 0.41 A
Why now. Engineering & Construction · market cap $35.1b. 17% off the 52-week high of $951.96. Revenue growing +17%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 7 sell-side analysts publish a mean 1-yr target of $1,000 (implying +27% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
28. VST — Vistra Corp. · score 73.7
Utilities - Independent Power Producers · price $157.22 · 1Y $222.89 · 5Y $281.39 · 10Y $360.88
FCF $1.8b C+ · Rev +19.1% B+ · D/E 3.55 D · P/E 26.3x C · PEG 0.45 A
Why now. Utilities - Independent Power Producers · market cap $53.0b. Down 28% from 52-week high of $219.82 — deep drawdown territory. Revenue growing +19%, comfortably above the S&P median. PEG 0.45 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $222.89 (implying +42% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 40% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $53.0b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. D/E 3.55 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $222.89 (analyst consensus (n=18)) — multiple re-rating thesis requires a catalyst. 5 yr $281.39 at ~12% CAGR — dividend + buyback compounding. 10 yr $360.88 if the moat survives secular pressure.
29. SE — Sea Limited · score 73.2
Internet Retail · price $105.00 · 1Y $140.26 · 5Y $205.35 · 10Y $304.62
FCF $4.5b B · Rev +36.4% A · D/E 0.28 A- · P/E 41.3x C · PEG 1.48 B
Why now. Internet Retail · market cap $64.3b. Down 47% from 52-week high of $199.30 — deep drawdown territory. Revenue growing +36% — in hypergrowth territory. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $140.26 (implying +34% upside).
Moat. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $64.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.55 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $140.26 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $205.35 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $304.62 if current growth sustains into durable earnings power.
30. TMUS — T-Mobile US, Inc. · score 72.9
Telecom Services · price $181.79 · 1Y $259.08 · 5Y $327.08 · 10Y $419.47
FCF $18.2b A- · Rev +8.5% B · D/E 2.19 C · P/E 19.3x B · PEG 0.70 A-
Why now. Telecom Services · market cap $196.7b. Down 30% from 52-week high of $261.56 — deep drawdown territory. PEG 0.70 — paying under fair value for the growth rate. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $259.08 (implying +43% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 173% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $196.7b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. D/E 2.19 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 30% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $259.08 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $327.08 at ~12% CAGR — dividend + buyback compounding. 10 yr $419.47 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.